TGF-{beta} trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance
At the ASCO 2024 meeting, Anthony P Conley, coauthor on this editorial, presented promising data from the phase 1/2 clinical trial called BETA PRIME (ClinicalTrials.gov NCT04673942) with AdAPT-001 plus a checkpoint inhibitor (CI). All participants gav…